Generali Asset Management SPA SGR Decreases Stock Holdings in Eli Lilly and Company $LLY

Generali Asset Management SPA SGR lowered its stake in Eli Lilly and Company (NYSE:LLY) by 4.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 67,722 shares of the company’s stock after selling 2,947 shares during the quarter. Eli Lilly and Company accounts for about 1.2% of Generali Asset Management SPA SGR’s portfolio, making the stock its 14th biggest holding. Generali Asset Management SPA SGR’s holdings in Eli Lilly and Company were worth $52,791,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $27,000. Citizens National Bank Trust Department boosted its stake in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, TD Capital Management LLC increased its position in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last ninety days. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $812.65 on Wednesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The stock has a market cap of $769.14 billion, a P/E ratio of 53.11, a PEG ratio of 1.17 and a beta of 0.47. The company has a 50-day moving average price of $744.36 and a 200 day moving average price of $765.86. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the business posted $3.92 EPS. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Finally, Morgan Stanley decreased their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $948.06.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.